PSMA

PSMA

PSMA Overview

Molecule Name
Prostate-Specific Membrane Antigen
Synonyms
FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP
Drug Development Progress
Drugs in Clinical Trials161
Approved Drugs6
Highest Development StageApproved
Target Synonym
EC:3.4.17.21,GIG27,Glutamate carboxypeptidase II,NAALADase I,FOLH,Cell growth-inhibiting gene 27 protein,PSM,N-acetylated-alpha-linked acidic dipeptidase I,GCPII,Folylpoly-gamma-glutamate carboxypeptidase,Folate hydrolase 1,FOLH1,Pteroylpoly-Gamma-Glutamate Carboxypeptidase,Membrane Glutamate Carboxypeptidase,Glutamate Carboxypeptidase 2,Glutamate Carboxylase II,NAALAD1,FGCP,PSMA,MGCP,Folate Hydrolase (Prostate-Specific Membrane Antigen) 1,N-Acetylated Alpha-Linked Acidic Dipeptidase 1,Prostate Specific Membrane Antigen Variant F,Prostate-Specific Membrane Antigen,EC 3.4.17.21,NAALAdase,GCP2
Background
Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.

PSMA Product List

Species
  • Human(6)
  • Mouse(3)
  • Cynomolgus(2)
  • Rat(1)
Tag
  • His Tag(6)
  • Fc Tag(2)
  • Fc Tag & Avi Tag(2)
  • His Tag & Avi Tag(2)
Host
  • HEK293(12)
Conjugate
  • Unconjugated(6)
  • Biotin-labeled(4)
  • FITC Labeled(1)
  • PE Labeled(1)
Grade
  • RUO(10)
  • PG (pre-GMP)(2)
Low Endotoxin
  • Yes(2)
  • No(10)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
PSMA
Mouse PSMA / FOLH1 Protein, His Tag (active enzyme) (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
Enzyme

$390.00

100ug
PSMA
Human PSMA / FOLH1 Protein, Fc Tag, premium grade
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$470.00

100ug
PSMA
HOTAvitag
PSA-H82Qb
Biotinylated Human PSMA / FOLH1 Protein, His,Avitag™, premium grade
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$415.00

25ug
PSMA
Human PSMA / FOLH1 Protein, His Tag, low endotoxin (active enzyme, MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLIEnzyme

$470.00

100ug
PSMA
Cynomolgus PSMA / FOLH1 Protein, His Tag, low endotoxin (active enzyme, MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISAEnzyme

$530.00

100ug
PSMA
Avitag
PSA-C82Q6
Biotinylated Cynomolgus PSMA / FOLH1 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
PSMA
Avitag
PSA-H82F7
Biotinylated Human PSMA / FOLH1 Protein, Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$415.00

25ug
PSMA
FITC-Labeled Human PSMA / FOLH1 Protein, His Tag
Human
HEK293
SDS-PAGE
ELISAFlow

$330.00

25ug
PSMA
PE-Labeled Human PSMA / FOLH1 Protein, His Tag (Site-specific conjugation)
Human
HEK293
Flow

$415.00

25tests
PSMA
Mouse PSMA / FOLH1 Protein, Fc Tag (MALS verified)
Mouse
HEK293
MALSSDS-PAGE

$435.00

100ug
You Have Viewed 1-10 Of 12 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

What validation data should I consider when selecting a PSMA reagent?

The relevant evidence depends on the intended application and may include purity, molecular characterization, enzymatic activity, antibody binding, or cell-based binding. Selected ACROBiosystems PSMA proteins include product-specific SDS-PAGE, SEC-MALS, ELISA, and flow-cytometry data, with the available evidence varying by catalog number. Researchers should prioritize validation that matches the planned assay rather than select a reagent based on tag or labeling format alone.

When should I use recombinant PSMA protein versus a PSMA-expressing cell line?

Recombinant PSMA proteins are useful for defined target-binding, antibody-characterization, and biochemical assay configurations, while PSMA-expressing cells provide the target in a cell-surface context. ACROBiosystems offers both recombinant PSMA reagents and a HEK293/Human PSMA stable cell line to support these complementary assay approaches. The appropriate format depends on whether the experiment requires a purified target or cell-surface PSMA presentation.

PSMA catalytic activity depends on homodimerization. What characterization supports recombinant PSMA selection for enzyme-inhibitor screening?

Select an active-enzyme PSMA format with both oligomeric-state characterization and substrate-hydrolysis data. ACROBiosystems provides MALS-verified PSMA and enzyme-activity validation for selected active-enzyme products. SEC-MALS supports assessment of dimeric assembly, while hydrolysis assays directly evaluate catalytic activity.

When should I select an enzymatically active PSMA / FOLH1 protein?

PSMA / FOLH1 is a zinc-dependent metallopeptidase, so an enzymatically active recombinant protein is relevant when the experimental question involves PSMA catalytic activity rather than target binding alone. ACROBiosystems provides selected human and mouse PSMA proteins explicitly identified as active enzymes and characterized by SEC-MALS. Enzyme activity and molecular characterization should be confirmed for the specific catalog number selected.

How should I choose among His-tagged, Fc-tagged, and biotinylated PSMA proteins?

Protein format should be matched to the planned immobilization, capture, and detection strategy. ACROBiosystems provides His- and Fc-tagged PSMA proteins as well as site-specifically biotinylated Avi-tag formats for compatible streptavidin-based workflows. Researchers should also compare species, construct, and product-specific bioactivity data rather than assume that different PSMA formats are interchangeable.

What types of PSMA / FOLH1 reagents are available for different assay needs?

ACROBiosystems provides recombinant PSMA / FOLH1 proteins together with selected labeled proteins, PSMA-coupled magnetic beads, antibodies, a stable cell line, and an ELISA kit. These formats support different experimental needs, from purified-target binding and enzymatic studies to cell-based target evaluation and detection. Reagent selection should therefore begin with the assay question rather than the product format alone.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
225 Actinium PSMA-617225Ac-PSMA-617; 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817Phase 3 ClinicalAdvanced Accelerator Applications Sa, Endocyte Inc, Novartis Pharma Ag
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
Gallium-68 PSMA-61768Ga-DKFZ-617; Gallium-68-PSMA-617; 68Ga-PSMA-33; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; 68Ga-PSMA-617; PSMA-617-[68Ga]; 225 Ac-PSMA-617Phase 3 ClinicalPeking Union Medical College Hospital
Carcinoma, Adenoid Cystic; Prostatic Neoplasms
Details
Ga-68 PSMA-093Ga-68 P16-093; PSMA-93 Latest; PSMA-093; HBED-CC-PHENOXY-PSMA; [68Ga]P16-093Phase 3 ClinicalFive Eleven Pharma Inc, Indiana University, Peking Union Medical College Hospital
Glioma; Kidney Neoplasms; Prostatic Neoplasms; Sjogren's Syndrome
Details
Vidoflufolastat (18F)CTT-1057-F-18; CTT-1057-18F; 18F-CTT1057; CTT-1057Phase 3 ClinicalCancer Targeted Technology Llc, Washington University
Carcinoma, Renal Cell; Prostatic Neoplasms
Details
Lu-177-labeled PSMA ligands (Zentralklinik Bad Berka/Johns Hopkins University School of Medicine)Phase 3 ClinicalZentralklinik Bad Berka
Kidney Neoplasms; Prostatic Neoplasms
Details
Lutetium-177 zadavotide guraxetanPhase 3 ClinicalCurium Us Llc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
INR-101INR101; INR-101; INR101 PET CT; INR101-PET/CTPhase 3 ClinicalCloud Nuclear Medicine (Tianjin) Co Ltd
Diagnostic agents; Prostatic Neoplasms
Details
68Ga-NYM03268Ga-NYM032; 68Ga-NY108; 68GaNYM032Phase 3 ClinicalWuxi Nuoyu Pharmaceutical Technology Co Ltd
Contrast agents; Prostatic Neoplasms
Details
Nizaracianine triflutateZW800-1Phase 3 ClinicalCuradel Surgical Innovations Inc, Leiden University Medical Center
Ureteral Diseases
Details
ITM-24DITM-24D; 68Ga-PSMA-TTMPhase 3 ClinicalITM Isotope Technologies Munich SE
Prostatic Neoplasms
Details
18F vipivotide tetraxetanAl18F-PSMA-617; 18F-PSMA-617Phase 3 ClinicalPeking Union Medical College Hospital
Prostatic Neoplasms
Details
HRS-4357HRS-4357; HRS4357Phase 3 ClinicalTianjin Hengrui Pharmaceutical Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
64Cu-PSMA I&TCu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T; Copper Cu 64 PSMA I&TPhase 3 ClinicalCurium Us Llc
Prostatic Neoplasms
Details
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals)Phase 3 ClinicalClarity Pharmaceuticals Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
177Lu-DOTA-rosopatamb177Lu-DOTA-TLX591-CHO; TLX591Phase 3 ClinicalTelix Pharmaceuticals Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
[Lu177]-PNT-2002PNT-2002; [Lu-177]-PNT-2002; 177Lu-PNT2002; [Lu-177]-PSMA-I&T; 177Lu-PSMA-I&TPhase 3 ClinicalScintomics
Carcinoma, Adenoid Cystic; Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
F-18 FlorastaminFC-303Phase 3 ClinicalFuturechem
Prostatic Neoplasms
Details
Lutetium-177-PSMA-I&TPhase 2 ClinicalRadboud University Nijmegen
Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Salivary Gland Neoplasms
Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA)Phase 2 ClinicalAdvanced Accelerator Applications Sa
Prostatic Neoplasms
Details
[18F]DCFBC[18F]DCFBCPhase 2 ClinicalSidney Kimmel Cancer Center, Washington University
Prostatic Neoplasms
Details
177Lu-PSMA-R2177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602Phase 2 ClinicalAdvanced Accelerator Applications Sa
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
89Zr-DFO-huJ591Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591Phase 2 ClinicalMemorial Sloan Kettering Cancer Center
Prostatic Neoplasms
Details
NezastomigREGN-5678Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
225Ac-J591225Ac-DOTA-J591; 225Ac-J591; CONV 01-α; J591-Ac-225Phase 2 ClinicalCornell University
Prostatic Neoplasms
Details
ATL-101J-591; Lu-177-J591; 177Lu-J591; muJ-591; huJ-591; MLN-591; MLN-591RL; ATL-101Phase 2 ClinicalWeill Medical College of Cornell University
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Glioma; Head and Neck Neoplasms; Kidney Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms
Details
[131I]MIP-10951095; [131I]MIP-1095; [131I]MIP-1466; 131I-MIP-1095; 131-I-MIP-1466; 131I-MIP-1466Phase 2 ClinicalProgenics Pharmaceuticals Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
225Ac-rhPSMA-10.1Phase 2 ClinicalBlue Earth Therapeutics Ltd
Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
CONV-01-alpha + PSMA I&TPhase 2 ClinicalConvergent Therapeutics Inc
Prostatic Neoplasms
Details
Terbium 161- PSMA I&TPhase 2 ClinicalOncosia Scientific GmbH
Prostatic Neoplasms
Details
[18F]PSMA-11F-18 PSMA-11; 18F-PSMA-11; [18F]-AlF-PSMA-11; [18F]AlF-PSMA-11Phase 2 ClinicalGhent University Hospital
Prostatic Neoplasms; Thyroid Neoplasms
Details
PB-011PB011; PB-011Phase 2 ClinicalPrimo Biotechnology Co Ltd
Neoplasms; Prostatic Neoplasms
Details
68Ga-PSMA-CYC68Ga-PSMA-CYCPhase 2 ClinicalFirst Affiliated Hospital Of Fujian Medical University
Prostatic Neoplasms
Details
TD-001TD-001Phase 2 ClinicalT.O.A.D. Oncology SA
Prostatic Neoplasms, Castration-Resistant
Details
MHB-048CMHB048C; MHB-048CPhase 2 ClinicalMinghui Pharmaceutical (Hangzhou) Co Ltd
Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
GSK-5458514GSK-5458514; GSK5458514Phase 2 ClinicalGlaxosmithkline Plc
Prostatic Neoplasms
Details
161Tb-NYM032161Tb-NYM032Phase 2 ClinicalInstitute Of Nuclear Physics And Chemistry Chinese Academy Of Engineering Physics, Mianyang Central Hospital, Wuxi Nuoyu Pharmaceutical Technology Co Ltd
Prostatic Neoplasms, Castration-Resistant
Details
INR-102[177Lu]Lu-PSMA-137; INR102; INR-102Phase 2 ClinicalCloud Nuclear Medicine (Tianjin) Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
RHN001-Dx (99mTc-PSMA)technetium-99m (99mTc); Technetium 99m-RHN 001; 99mTc-RHN001Phase 2 ClinicalHeidelberg University Hospital, Telix Pharmaceuticals Ltd
Prostatic Neoplasms
Details
RHN001-Tx (188Re-PSMA)rhenium-188- RHN 001; RHN001-Tx (188Re-PSMA); Rhenium-188 RHN 001 (188Re)Phase 2 ClinicalHeidelberg University Hospital, Telix Pharmaceuticals Ltd
Prostatic Neoplasms
Details
AS-1986NSAS-1986NS; AS1986NSPhase 2 ClinicalAntelope Surgical Solutions Inc
Prostatic Neoplasms
Details
GenSci-143GenSci-143; GenSci143Phase 2 ClinicalChangchun GeneScience Pharmaceuticals Co Ltd
Alzheimer Disease; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
225Ac-LNC1011225Ac-LNC-1011; 225Ac-LNC1011Phase 2 ClinicalYantai Lannacheng Biotechnology Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
In-111 rosopatamab tetraxetanPhase 2 ClinicalConvergent Therapeutics Inc
Prostatic Neoplasms, Castration-Resistant
Details
Ac-225 rosopatamab tetraxetanPhase 2 ClinicalConvergent Therapeutics Inc
Prostatic Neoplasms, Castration-Resistant
Details
68Ga-PSMA-0057Phase 2 ClinicalSuzhou Ruihe Pharmaceutical Technology Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
177Lu-LNC1011177LuLNC1011; 177Lu-LNC1011Phase 2 ClinicalYantai Lannacheng Biotechnology Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
DGPR-1008DGPR1008; DGPR-1008Phase 2 ClinicalXindou Biotechnology (Suzhou) Co Ltd
Contrast agents; Prostatic Neoplasms
Details
177Lu-NYM032177Lu-NYM032; 177LuNYM032; 177Lu-NY108Phase 2 ClinicalWuxi Nuoyu Pharmaceutical Technology Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
177Lu-PSMA-0057177Lu-PSMA-0057Phase 2 ClinicalNanjing First Hospital, Nanjing Medical University
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
[225Ac]Ac-PSMA-R2[225Ac]Ac-PSMA-R2; AAA802; AAA-802Phase 2 ClinicalNovartis Pharma Ag
Prostatic Neoplasms
Details
177Lu-PSMA177Lu-PSMAPhase 2 ClinicalIstituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori
Carcinoma, Renal Cell; Neoplasm Metastasis; Neoplasms; Prostatic Neoplasms
Details
[177Lu]JH020002[177Lu]JH020002; JH-002; JH002; 177-Lu JH-020002; Lu 177 JH020002; JH02; JH-02Phase 2 ClinicalBivision Biomedical Technology (Nanjing) Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
131I-PSMA-1095131I-PSMA-1095Phase 2 ClinicalJewish General Hospital
Prostatic Neoplasms
Details
68Ga-HTK0314968Ga-HTK03149Phase 2 ClinicalBritish Columbia Cancer Agency
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
177Lu-HTK03170177Lu-HTK03170Phase 2 ClinicalBritish Columbia Cancer Agency
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
ADVC-001212Pb-ADVC001; 212 Pb ADVC 001; 212-lead ADVC 001; 212Pd ADVC001; [212Pb]Pb-ADVC-001; ADVC-001Phase 2 ClinicalAdvancell Advanced In Vitro Cell Technologies Sa
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
Ga-68-NGULPhase 2 ClinicalCellbion Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute
Leukemia, B-Cell; Lymphoma, B-Cell
Details
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR GD2/PSMAPhase 2 ClinicalShenzhen Geno-Immune Medical Institute
Solid tumours
Details
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute)bi-4SCAR PSMA/CD70Phase 2 ClinicalShenzhen Geno-Immune Medical Institute
Neoplasms
Details
177Lu-rhPSMA-10.1177Lu-rhPSMA-10.1; 177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu-rhPSMA; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu rhPSMA-10.1Phase 2 ClinicalTechnical University Munich
Prostatic Diseases; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urogenital Neoplasms
Details
Lu-177-DGULLu-177-DGUL; 177Lu-DOTA-GUL; PSMA-D GULPhase 2 ClinicalCellbion Co Ltd
Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
225Actinium-PSMA-I&TFPI-2265Phase 2 ClinicalExcel Diagnostics And Nuclear Oncology Center
Prostatic Neoplasms, Castration-Resistant
Details
OlsutamigREGN-4336Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Prostatic Neoplasms, Castration-Resistant
Details
[177Lu]Ludotadipep177Lu-FC705; 177Lu-FC-705Phase 2 ClinicalFuturechem
Prostatic Neoplasms, Castration-Resistant
Details
67Cu-SAR-bisPSMAPhase 2 ClinicalClarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
Details
99m-TC-PSMA-I&SPhase 2 ClinicalIrccs San Raffaele
Prostatic Neoplasms
Details
IS-002IS-002Phase 2 ClinicalIntuitive Surgical Medical Device Science & Technology (Shanghai) Co Ltd
Prostatic Neoplasms
Details
ZopocianineOTL-78; OTL78Phase 2 ClinicalEndocyte Inc, Purdue University
Prostatic Neoplasms
Details
INO-5401INO-5401Phase 2 ClinicalInovio Pharmaceuticals Inc
Carcinoma, Transitional Cell; Glioblastoma
Details
JNJ-63898081JNJ-63898081; JNJ-8081Phase 1 ClinicalJohnson & Johnson Innovative Medicine
Neoplasms
Details
P28z-CARP28z-CARPhase 1 ClinicalMemorial Sloan Kettering Cancer Center, United States Department Of Defense
Prostatic Neoplasms
Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory)Phase 1 ClinicalBRL Medicine Inc
Prostatic Neoplasms, Castration-Resistant
Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical CenterPhase 1 ClinicalRoger Williams Medical Center
Prostatic Neoplasms
Details
CC-1CC-1Phase 1 ClinicalBiconY Therapeutics Gmbh
Prostatic Neoplasms
Details
AcapatamabAMG-160Phase 1 ClinicalAmgen Inc
Carcinoma, Non-Small-Cell Lung; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
177Lu-EB-vipivotide tetraxetan[177Lu]Lu-XT033; 177-Lu-EB-PSMA-617Phase 1 ClinicalBeijing Xiantong International Technology Co Ltd, Peking Union Medical College Hospital
Carcinoma, Adenoid Cystic; Carcinoma, Renal Cell; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
[177Lu]-CTT-1403CTT-1403; [177Lu]CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403Phase 1 ClinicalCancer Targeted Technology Llc
Prostatic Neoplasms
Details
Pelgifatamab corixetanBAY-2315497Phase 1 ClinicalBayer AG
Prostatic Neoplasms, Castration-Resistant
Details
anti-PSMA CAR T-cell therapy (Memorial Sloan-Kettering Cancer Center)Phase 1 ClinicalMemorial Sloan Kettering Cancer Center
Prostatic Neoplasms
Details
PSMA CAR-TPhase 1 ClinicalUniversity Of Pennsylvania
Hormone-Resistant Prostate Neoplasms; Prostatic Neoplasms
Details
PSMA/NKG2DL/FAP-targeted Hi-TCR-T cellsPhase 1 ClinicalShenzhen Misheng Biotechnology Co Ltd
Prostatic Neoplasms; Solid tumours
Details
INO-5412INO-5412; INO5412Phase 1 ClinicalInovio Pharmaceuticals Inc
Glioblastoma
Details
161Tb-LNC1011161Tb-LNC1011Phase 1 ClinicalYantai Lannacheng Biotechnology Co Ltd
Prostatic Neoplasms
Details
225Ac-TR2205225Ac-TR2205Phase 1 ClinicalCancer Hospital of Shandong First Medical University
Triple Negative Breast Neoplasms
Details
Chimeric Antigen Receptor T Cells therapy (Orig Stone Biotech)ACT#001Phase 1 ClinicalOrig Stone Biotech(Zhejiang) Co Ltd
Prostatic Neoplasms, Castration-Resistant
Details
BAY2616505BAY-2616505Phase 1 ClinicalBayer AG
Prostatic Neoplasms, Castration-Resistant
Details
177Lu-TWS02Phase 1 ClinicalShandong University, The Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University
Prostatic Neoplasms
Details
225Ac-TWS02Phase 1 ClinicalShandong University, The Affiliated Huaian No.1 People'S Hospital Of Nanjing Medical University
Prostatic Neoplasms
Details
18F-(FAl)-PSMAPhase 1 ClinicalPla General Hospital
Prostatic Neoplasms
Details
177Lu-PSMA-3QPhase 1 ClinicalThe First Medical Center Of Chinese People'S Liberation Army General Hospital
Prostatic Neoplasms
Details
18F-P13718F-P137Phase 1 ClinicalThe First Affiliated Hospital Of Beijing University
Nasopharyngeal Carcinoma; Neoplasms
Details
177Lu-ITG-PSMA-1177Lu-ITG-PSMA-1; 177Lu-PSMA-I&T; Lu-177-ITG-PSMA-1Phase 1 ClinicalLausanne University Hospital
Prostatic Neoplasms, Castration-Resistant; Sarcoma
Details
[64Cu]Cu-PSMA-R2Phase 1 ClinicalInstitut De Cancerologie De L Ouest
Prostatic Neoplasms
Details
Anti-PSMA CAR-NK cell therapy (Cancer Hospital Of Chinese Academy Of Medical Sciences)Phase 1 ClinicalCancer Hospital Of Chinese Academy Of Medical Sciences
Prostatic Neoplasms, Castration-Resistant
Details
[111In]In-FL-020Phase 1 ClinicalFull Life Technologies Ltd
Prostatic Neoplasms, Castration-Resistant
Details
PSMA-VG-01PSMA-VG-01Phase 1 ClinicalVitsGen Therapeutics Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
[177Lu]Lu-PSMA-XT[177Lu]Lu-PSMA-XTPhase 1 ClinicalBeijing Xiantong International Technology Co Ltd
Prostatic Neoplasms, Castration-Resistant
Details
64Cu-TR220564Cu-TR2205; 64CuTR2205Phase 1 ClinicalC-Ray Therapeutics (Chengdu) Co Ltd
Diagnostic agents; Prostatic Neoplasms
Details
ART-101 (Archeus Technologies)ART-101Phase 1 ClinicalUniversity of Wisconsin–Madison
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
ITM-23ITM-23; 161Tb- ITM23Phase 1 ClinicalItm Solucin Gmbh
Prostatic Neoplasms
Details
[18F]F-DCFPyL[18F]F-DCFPyLPhase 1 ClinicalAnhui Provincial Hospital
Prostatic Neoplasms
Details
[18F]AlF-PSMA-N5[18F]AlF-PSMA-N5Phase 1 ClinicalAnhui Provincial Hospital
Prostatic Neoplasms
Details
[177Lu]Lu-BQ7876[177Lu]Lu-BQ7876; Lutetium-177 Labeled BQ7876Phase 1 ClinicalTomsk National Research Medical Center Of The Russian Academy Of Sciences
Prostatic Neoplasms
Details
68Ga-AAZTA-NI-093Phase 1 ClinicalFirst Affiliated Hospital Of Fujian Medical University
Prostatic Neoplasms
Details
61Cu-based NuriPro radiodiagnostic (NUCLIDIUM)Phase 1 ClinicalNuclidium AG
Prostatic Neoplasms
Details
IR800-IAB2MAIR800-IAB2MAPhase 1 ClinicalImaginab Inc
Kidney Neoplasms; Prostatic Neoplasms
Details
177Lu-TR0471177Lu-TR0471; 177LuTR0471Phase 1 ClinicalC-Ray Therapeutics (Chengdu) Co Ltd
Prostatic Neoplasms, Castration-Resistant
Details
[18F]F-PSMA-N5[18F]F-PSMA-N5Phase 1 ClinicalAnhui Provincial Hospital
Prostatic Neoplasms
Details
PSW-1025PSW-1025Phase 1 ClinicalJapan Agency For Medical Research And Development, Osaka University
Prostatic Neoplasms
Details
68Ga-AAZTA-09368Ga-AAZTA-093Phase 1 ClinicalFirst Affiliated Hospital Of Fujian Medical University
Prostatic Neoplasms
Details
225Ac-ITM-22ITM-22Phase 1 ClinicalITM Radiopharmazie Munchen GmbH
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
99mTc-QULIC-5-P199mTc-QULIC-5-P1Phase 1 ClinicalFirst Affiliated Hospital Of Chongqing Medical University
Prostatic Neoplasms
Details
68Ga-PSFA68Ga-PSFAPhase 1 ClinicalFirst Affiliated Hospital Of Chongqing Medical University
Adenomatous Polyposis Coli
Details
161Tb-SibuDABPhase 1 ClinicalUniversity Hospital Basel
Prostatic Neoplasms, Castration-Resistant
Details
Actinium-225 FL 020 (Full-Life Technologies)225-Ac FL-020; 225Ac-FL-020Phase 1 ClinicalFull Life Technologies Ltd
Prostatic Neoplasms, Castration-Resistant
Details
[Ac-225]-PSMA-62[Ac-225]-PSMA-62; 225Ac-PSMA-62Phase 1 ClinicalPoint Biopharma Inc
Hormone-Sensitive Prostate Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
111In-PSMA-TrilliumBAY3632687; BAY-3632687Phase 1 ClinicalBayer AG
Prostatic Neoplasms, Castration-Resistant; Prostatism
Details
JNJ-9401JNJ-9401Phase 1 ClinicalXencor Inc
Prostatic Neoplasms
Details
68Ga-NTA-47668Ga-NTA-476Phase 1 Clinical3B Pharmaceuticals GmbH, Genesiscares
Prostatic Neoplasms
Details
ABBV-969ABBV-969; ABBV969Phase 1 ClinicalAbbvie Inc
Prostatic Neoplasms, Castration-Resistant
Details
BAY-3563254BAY-3563254; BAY3563254Phase 1 ClinicalNoria Therapeutics Inc, PSMA Therapeutics Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatism
Details
JNJ-87189401JNJ-87189401Phase 1 ClinicalJanssen Research & Development Llc
Prostatic Neoplasms
Details
99mTc-SY101[99mTc]SY101; 99mTc-SY101; 99mTcSY101Phase 1 ClinicalShanghai Shiya Pharmaceutical Technology Co Ltd
Contrast agents; Prostatic Neoplasms
Details
Actinium-225-macropa-pelgifatamabBAY-3546828; BAY3546828Phase 1 ClinicalBayer AG
Prostatic Neoplasms, Castration-Resistant
Details
AMX-500VIR-5500; SAR-446329; SAR446329; AMX-500Phase 1 ClinicalAmunix Pharmaceuticals Inc
Prostatic Neoplasms, Castration-Resistant
Details
[68Ga]Ga-PSMA-D5[68Ga]Ga-PSMA-D5Phase 1 ClinicalAnhui Provincial Hospital
Prostatic Neoplasms
Details
177Lu-LNC1003177Lu-LNC1003Phase 1 ClinicalYantai Lannacheng Biotechnology Co Ltd
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
HRS-9815HRS-9815; HRS9815Phase 1 ClinicalTianjin Hengrui Pharmaceutical Co Ltd
Diagnostic agents; Prostatic Neoplasms
Details
PSMA-Targeted [In-111]-Labeled Trillium CompoundPhase 1 ClinicalRatio Therapeutics Inc
Prostatic Neoplasms
Details
Autologous T cells therapy(Unicar-Therapy)Phase 1 ClinicalShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Prostatic Neoplasms
Details
212Pb-NG001212Pb-NG001; AB-001; AB001Phase 1 ClinicalARTBIO Inc
Prostatic Neoplasms, Castration-Resistant
Details
CART-PSMA cells(Nova Therapeutics)Phase 1 ClinicalNova Therapeutics LLC
Prostatic Neoplasms
Details
177Lu-P17-088177Lu-P17-088Phase 1 ClinicalPeking Union Medical College Hospital
Prostatic Neoplasms, Castration-Resistant
Details
177Lu-P17-087177Lu-P17-087Phase 1 ClinicalPeking Union Medical College Hospital
Prostatic Neoplasms, Castration-Resistant
Details
JANX-007PSMA-TRACTr; JANX-007Phase 1 ClinicalJanux Therapeutics Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
JNJ-80038114JNJ-80038114Phase 1 ClinicalJanssen Research & Development Llc
Prostatic Neoplasms
Details
CART-PSMA-TGFbRDN (University of Pennsylvania)Phase 1 ClinicalUniversity Of Pennsylvania
Prostatic Neoplasms
Details
DXC-014DAC-014; DXC-014Phase 1 ClinicalHangzhou Dac Biotech Company Ltd
Melanoma; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours
Details
DXC-008DAC-008; DXC-008Phase 1 ClinicalHangzhou Dac Biotech Company Ltd
Prostatic Neoplasms; Sarcoma, Ewing; Solid tumours
Details
TNB-585TNB-585; AMG-340Phase 1 ClinicalTeneobio Inc
Prostatic Neoplasms, Castration-Resistant
Details
CB-307CB-307; CB307Phase 1 ClinicalCrescendo Bioscience Inc
Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
Copper 64-DOTA-TLX 59264Cu-TLX-592; 64Cu-DOTA-TLX592Phase 1 ClinicalTelix International Pty Ltd
Prostatic Neoplasms
Details
ARX-517JNJ-95298177; ARX-517; ARX517Phase 1 ClinicalAmbrx Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
AVC-102AVC-102Phase 1 ClinicalAvenCell Therapeutics Inc
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Kidney Neoplasms; Prostatic Neoplasms
Details
CBP-1018CBP-1018Phase 1 ClinicalCoherent Biopharma Suzhou Co Ltd
Carcinoma, Renal Cell; Lung Neoplasms; Prostatic Neoplasms; Solid tumours
Details
CCW-702CCW-702Phase 1 ClinicalAbbvie Inc, The Scripps Research Institute Inc
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics)Phase 1 ClinicalSorrento Therapeutics Inc
Neoplasms
Details
CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics)TmPSMA-02Phase 1 ClinicalTmunity Therapeutics Inc, University Of Minnesota, University Of Pennsylvania
Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
[99mTc]TcO-ABX-474ClinicalHelmholtz-Zentrum Dresden-Rossendorf
Prostatic Neoplasms
Details
radiolabeled AZ-093 (Five Eleven Pharma/University of Pennsylvania)[68Ga]- AZ-093; AZ-093; AZ-093-[177Lu]; AZ-093-68Ga; Lutetium-177-AZ-093; [177Lu]-AZ-093; AZ-093-[68Ga]; AZ-093-177Lu; Gallium-68-AZ-093ClinicalUniversity Of Pennsylvania
Prostatic Neoplasms
Details
177Lu-PSMA-1ClinicalCentre Léon Bérard
Carcinoma, Renal Cell; Peritoneal Neoplasms; Prostatic Neoplasms
Details
(99m)Tc-MIP-1427(99m)Tc-MIP-1427; 99mTc-MIP-1427ClinicalMolecular Insight Pharmaceuticals Inc
Prostatic Neoplasms
Details
99mTc-P13799mTc-P137ClinicalThe First Affiliated Hospital Of Beijing University
Neoplasms
Details
18F-TWS0218F-TWS02ClinicalShandong University
Prostatic Neoplasms
Details
[68Ga]Ga-TWS0268Ga-TWS02ClinicalShandong University
Prostatic Neoplasms
Details
68Ga-PSMAClinicalThe First Affiliated Hospital Of Anhui Medical University
Prostatic Neoplasms
Details
[68Ga]-P137ClinicalBeijing Cancer Hospital
Prostatic Neoplasms
Details
177Lu-PSMA-3D1015Clinical3d Medicines Inc
Prostatic Neoplasms, Castration-Resistant
Details
[At-211] PSMA-5[At-211] PSMA-5ClinicalOsaka University
Prostatic Neoplasms
Details
⁶⁸Ga-labeled PSMA-targeting tracer (FindCure Biosciences )FindCure Biosciences (ZhongShan) Co Ltd
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Capromab pendetidelndium-CYT-356; CYT-356; Indium-111-CYT-356; 111In CYT-356ApprovedEusa PharmaProstaScintUnited StatesProstatic NeoplasmsCytogen Corp1996-10-28
Prostatic Neoplasms
Details
PB-01 (Primo Biotechnology)PSMA-1007-[18F]; PB-01 (Primo Biotechnology); PB01 [18F]PSMA-1007; 18F PSMA-1007; [18F]PSMA1007; 18FPSMA-1007; [18F]PSMA-1007; 18F-PSMA-1007; [18F]PSMA 1007ApprovedPrimo Biotechnology Co LtdRadelumin
Carcinoma, Renal Cell; Colonic Neoplasms; Prostatic Neoplasms
Details
Piflufolastat F 18ApprovedJohns Hopkins UniversityPylarify, PylclariUnited StatesProstatic NeoplasmsProgenics Pharmaceuticals Inc2021-05-26
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Castration-Sensitive Prostate Neoplasms; Diagnostic agents; Genital Neoplasms, Female; Metastatic breast cancer; Neoplasm Metastasis; Pancreatic Neoplasms; Prostatic Neoplasms
Details
TLX-591 companion diagnostic (Telix Pharmaceuticals)Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11; AAA517; AAA-517; [68Ga]Ga-PSMA-11; TLX591-Sx; 68Ga-PSMA-IRDye; TLX591-CDx; TLX007-CDxApprovedAdvanced Nuclear Medicine Ingredients (Anmi)Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, LocametzUnited StatesProstatic NeoplasmsTelix Pharmaceuticals Ltd, University Of California, Los Angeles2020-12-01
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Diagnostic agents; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms
Details
Lutetium (177Lu) vipivotide tetraxetanPSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617; Lu-177- RLTApprovedRadiomedix IncPLUVICTO, 派威妥United StatesProstatic Neoplasms, Castration-ResistantNovartis Pharmaceuticals Corp2022-03-23
Anemia; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Verrucous; Cytopenia; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia
Details
Flotufolastat F-18F-18-rhPSMA-7.3; Fluorine-18 rhPSMA; rhPSMA-7.3 (18F); 18FrhPSMA-7.3; (18F)-rhPSMA-7.3; 18F-rhPSMA-7.3ApprovedBlue Earth Diagnostics Inc, Technical University MunichPOSLUMAUnited StatesProstatic NeoplasmsBlue Earth Diagnostics Ltd2023-05-25
Contrast agents; Prostatic Neoplasms
Details
Customer Reviews
  • M***n2025-09-15
    I have several Scientists that use Acro Proteins. We used to order these on Fisher, however, I have now changed to directly through Acro as their ordering is so much easier and they fulfill order promptly and perfectly. We are starting to use more Acro products and I am excited to continue to work with this company and keep getting the same great quality of products, ease of ordering, and super quick fulfillment.
  • T***n2023-06-29
    I ordered this product on Monday and received it by Friday! The product came neatly packed in dry ice with secure packaging. The reagent gave me good standard curves as I titrate the concentration of PSMA for my assay. I will order again next time.
  • T***n2021-09-22
    I highly recommend for this supplier company .I received this order on Sep . 03 /2021 with enough dry ice for - 80C. Thank you acrobiosystems.